Figure 1
The 54 breakpoints and 31 partners genes of MLL known so far.
TO THE EDITOR
Genomics is a recent field of the sciences, with fast growth. For instance, a rapidly increasing number of (genetic) disorders of the cell have proved to be targets for cancer. Data are evolving permanently, and it has become a real task to make available the state of the art to the medical community. Yet, data on genomic changes in cancer have crucial importance in diagnostic ascertainment, prognostic evaluation, and treatment decisions. About 300 different haematologic malignancies can be classified according to a given chromosome aberration, often implying a given prognosis, [1] [2] [3] and a thousand genes are more or less implicated in cancer. There is a need for databases collecting and summarising the knowledge accumulated from researchers and clinicians. We present an example of such databases, the 'Atlas of Genetics and Cytogenetics in Oncology and Haematology' 4 URL: http://www.infobiogen.fr/services/chromcancer; this is a database of free access on the Internet devoted to chromosome abnormalities in cancer, cancer-prone diseases, and genes involved in cancer. It presents information in the form of concise and updated reviews (cards). It is complementary to the Catalog of Chromosome Aberrations in Cancer. 2 It is part of the genome project, and a tie in the genetics network; it is also a portfolio dedicated to chromosomes from bands to sequence. The Atlas is a peer-reviewed on-line journal and database, and, as such, it is indexed by the Current Web Contents.
The site is presented in the following way: Cards on (1) genes, (2) cytogenetic/clinical entities in hematology, (3) solid tumours, and (4) cancer-prone diseases represent the body of the Atlas. Cards on genes include data on DNA, RNA, and protein, mutations, and diseases where this gene is implicated. Cards on cytogenetic entities, on clinical entities in haematology, and cards on solid tumours include data Deep insights are papers focusing on a specific aspect and/or on related subjects on the periphery of our domains, for better understanding; they appear as traditional review articles.
A very large and up-to-date portal has also been developed, including the genome centres and resources, and more than 80 on-line journals. This is our contribution to the network. Reciprocally, important databases such as HUGO (Human Genome Organization), CancerNet (National Cancer Institute), Resources For Molecular Cytogenetics, GeneCards, Guide to Internet Resources for Cancer, Orphanet, and Cancer GeneWeb include extensive hyperlinks to our Atlas.
Educational items are being developed. Contributions and collaborations are welcome (including iconography on chromosomes). It will serve the entire community of clinicians and researchers in these areas. A hundred and twenty collaborators have already contributed with more than 350 papers. More than 6000 individual machines connect to us each month. If/when the whole community participates in the Atlas, any new item, any new knowledge, will promptly update our common tool.
Below, as an example, are parts of the card '11q23 rearrangements in leukaemia'. This card reviews the various leukaemia types where MLL is involved, with precise proportions of the different FAB according to the different cytogenetic entities; it is updated and it is likely to be the only place to find described the 54 breakpoints and 31 partners genes of MLL known so far.
Leukemia Table 1 11q23 and MLL partners (full text in: http://www.infobiogen.fr/services/chromcancer/Anomalies/11q23ID1030.html)
Disease
De novo and therapy-related leukaemias; acute nonlymphocytic leukaemia (ANLL) and acute lymphocytic leukaemia (ALL) grossly represent half the cases each; myelodysplasia (MDS) in the remaining 5%; biphenotypic leukaemia at times (likely to be more frequent with more investigations); 11q23 rearrangements in treatment-related leukaemias (5-10% of 11q23 cases) are found mainly following a treatment with anti-topoisomerase II, or an intercalating topoisomerase II inhibitor, but also after alkylating agent treatment and/or radiotherapy; the prior cancer is variable. ANLL M5a in half cases, M4 (20%), M1 or M5b (10% each), M2 (5%); ALL: B cell mostly, L1 or L2, CD19 + in 60% of B-ALL cases, CD10 + 35%; T-ALL in rare cases (Ͻ1%); MDS: most often RA or RAEB±T. Epidemiology 25% are infant (Ͻ1 yr) cases; children and adults each represent 50% of cases; M/F = 0.9 (Nonsignificant).
Cytogenetics (Figure 1 ) I. The most frequent are: ¼ normal karyotype: a partial tandem duplication (in situ) of MLL is present in a percentage of ANLL with a normal karyotype; LARG, in 11q23, has been found fused to MLL. ¼ +11: 1% of ANLL and MDS as well; M1, M2, and M4 ANLL; therapy-related ANLL; MDS evolving towards ANLL; partial tandem duplication (in situ) of MLL; visible dup(11q) also occur. ¼ t(4;11)(q21;q23): represent 1/3 of cases; found mainly (95%) in B-ALL (CD19 + in 75%, CD10 + in 15%); treatment-related ALL in 5%; unbalanced sex ratio Ͻ4 yrs (1M/2F); children represent half cases (infants (Ͻ1 yr) accounting for 1/3 of all cases); children aged 2-9 yrs appear to have a much better prognosis; the gene involved in 4q21 is AF4. ¼ t(6;11)(q27;q23): 5% of cases; mostly children and young adults; male predominance; the gene involved in 6q27 is AF6. ¼ t(9;11)((p23;q23): represent 1/4 of cases; found in ANLL mainly in M5a (70%), or M4 (10%); in ALL in 10%; de novo and therapy-related AL; children represent half the cases (infants (Ͻ1 yr) accounting for 15% of all cases); the gene involved in 9p22 is AF9. ¼ t(10;11)(p12;q23): 5% of cases; M4 or M5 ANLL; ALL at times; from infants and children to (rare) adult cases; the gene involved in 10p12 is AF10. ¼ t(11;19)(q23;p13.1): 5% of cases; M4 or M5 ANLL most often; de novo and therapy-related AL; adults mainly; the gene involved in 19p13.1 is ELL. ¼ t(11;19)(q23;p13.3): 5% of cases; ALL, biphenotypic AL, and ANLL (M4/M5 mainly); therapy-related AL; T cell ALL at times, these T cell cases are the only cases of t(11;19) with an excellent prognosis, a rather rare feature in this page!!; mostly found in infants (half cases), and other children (altogether: 70%), or young adults (cases Ͼ40 yrs are 4%; from 23 unpublished cases and a review of 90 cases); the gene involved in 19p13.3 ENL.
II. Various other 11q23 rearrangements have been described; these are rare, some are even poorly known, but the ones listed below are recurrent and/or with ascertainment of a partner gene to MLL: ¼ inv(11)(p15q23): ANLL and MDS. ¼ del(11q): one case (t-ANLL) showed involvement of GAS7, a gene located in 17p13; del(11q) with MLL rearrangement is likely to be heterogeneous, as MLL shows multiple possible partners, and, not rarely, complex translocations. ¼ t(X;11)(q13;q23): ANLL; the gene involved in Xq13 is AFX1. ¼ t(X;11)(q22;q23); the gene in Xq22 is Septin2. ¼ t(1;11)(p32;q23): ALL and ANLL; the gene involved in 1p32 is AF1P. ¼ t(1;11)(q21;q23): mostly M4 ANLL; the gene involved in 1q21 is AF1q. ¼ t(2;11)(p21;q23): ANLL and MDS; may be found associated with del(5q). ¼ t(2;11)(q11;q23); the gene in 2q11 is LAF4. ¼ t(3;11)(p21;q23); the gene involved in 3p21 is AF3p21. ¼ t(3;11)(q25;q23); the gene in 3q25 is GMPS. ¼ t(5;11)(q31;q23), ins(5;11)(q31;q13q23); the latter involve AF5q31 in 5q31. ¼ t(5;11)(q31;q23); the gene in 5q31 is GRAF. ¼ t(6;11)(q21;q23): ANLL; the gene in 6q21 is AF6q21. ¼ t(9;11)(q34;q23); the gene in 9q34 is AF9q34. ¼ t(10;11)(p11.2;q23); the gene in 10p11.2 is ABI1. ¼ t(10;11)(q22;q23). ¼ t(11;11)(q13;q23). ¼ t(11;12)(q23;q13). ¼ t(11;14)(q23;q24); the gene in 14q24 is h-gephyrin. ¼ t(11;15)(q23;q14); the gene in 15q14 is AF15q14. ¼ t(11;15)(q23;q15). ¼ t(11;16)(q23;p13): treatment-related ANLL/MDS; most cases are children cases; the gene involved in 16p13 CBP. ¼ t(11;17)(q23;p13); the gene in 17p13 is GAS7. ¼ t(11;17)(q23;q12); the gene in 17q12 is RARa. ¼ t(11;17)(q23;q21): ANLL; the gene involved in 17q21 is AF17. ¼ t(11;17)(q23;q25): ANLL and MDS; the gene in 17q25 is MSF/AF17q25. ¼ t(11;18)(q23;q23). ¼ t(11;19)(q23;p13): ANLL; the gene in 19p13 is EEN. ¼ t(11;21)(q23;q11). ¼ t(11;22)(q23;q13): ANLL; the gene in 22q13 is P300. ¼ t(11;22)(q23;q11.2): ANLL; the gene in 22q11.2 is hCDCRel.
III.Finally, various other breakpoints with 11q23 have been described, but without gene ascertainment: Xq24, 1q32, 2q37, 7q22, 7q32, 8q11, 9p11, 9q33, 12p13, 12q24, 14q11, 14q32, 17q11, 18q12, 20q13, % Additional anomalies: +X and i(7q) in the t(4;11); +8, +19, +21 in the t(6;11); +8 and +19 in the t(9;11); inv(11) in the t(10;11); +X, +6 and +8 in the 19p13.3; +8 in the 19p13.1.
End of the paragraphs taken from the card '11q23 rearrangements in leukaemia'.
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TO THE EDITOR
BCR-ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemia.
1 BCR-ABL has been found in most patients with chronic myelogenous leukemia (CML) and in about 30% of adult patients with acute lymphoblastic leukemia (ALL). Targeting the tyrosine kinase activity of BCR-ABL may be a feasible strategy towards improved therapy for Ph-positive leukemia.
2 The 2-phenylaminopyrimidine derivative STI571 is a recently designed tyrosine kinase inhibitor that competitively inhibits ATP binding in the kinase Correspondence: A Nakajima; Fax: 813 5381 6651
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